References
1. Singh JA, Beg S, Lopez‐Olivo MA. Tocilizumab for rheumatoid arthritis. Cochrane Database of Systematic Reviews . 2010;(7)doi:10.1002/14651858.CD008331.pub2
2. Pawar A, Desai RJ, Solomon DH, et al. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study. Annals of the Rheumatic Diseases . 2019;78(4):456-464. doi:10.1136/annrheumdis-2018-214367
3. Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJK. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology . 2010;50(3):552-562. doi:10.1093/rheumatology/keq343
4. Nguyen MT, Pødenphant J, Ravn P. Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab.BMJ Case Reports . 2013;2013:bcr2012007413. doi:10.1136/bcr-2012-007413
5. Berman M, Ben-Ami R, Berliner S, et al. The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature. Life . 2021;11(3):258.
6. Reisinger AC, Hermann J, Vagena FR, Hackl G, Eller P. Tuberculosis sepsis after tocilizumab treatment. Clinical Microbiology and Infection . 2020;26(11):1493-1494. doi:10.1016/j.cmi.2020.05.030
7. Peng J, Fu M, Mei H, et al. Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis. Reviews in Medical Virology . 2022;32(3):e2295. doi:https://doi.org/10.1002/rmv.2295
8. Pettit NN, Nguyen CT, Mutlu GM, et al. Late onset infectious complications and safety of tocilizumab in the management of COVID-19.Journal of Medical Virology . 2021;93(3):1459-1464. doi:https://doi.org/10.1002/jmv.26429
9. Lidid L, Valenzuela J, Villarroel C, Alegria J. Crossing the barrier: when the diaphragm is not a limit. AJR Am J Roentgenol . 2013;200(1):W62-70.